Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Equity Income (2024 - 2025)

BioNexus Gene Lab's Equity Income history spans 2 years, with the latest figure at $23742.0 for Q2 2025.

  • For Q2 2025, Equity Income fell 73.18% year-over-year to $23742.0; the TTM value through Sep 2025 reached -$145351.0, changed N/A, while the annual FY2024 figure was $69476.0, 77.34% down from the prior year.
  • Equity Income for Q2 2025 was $23742.0 at BioNexus Gene Lab, up from $4514.0 in the prior quarter.
  • Across five years, Equity Income topped out at $88532.0 in Q2 2024 and bottomed at -$173607.0 in Q4 2024.